On May 1, 2026, Purdue Pharma permanently ceased operations. Knoa Pharma, a new and different company, will distribute medicines formerly distributed by Purdue Pharma. For inquiries about a Knoa Pharma or Purdue Pharma medicine, or to report an adverse event or product complaint, click here.

The First in Class, Alkylator‑Histone‑Deacetylase‑Inhibitor Fusion Molecule EDO‑S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro‑Apoptotic Signaling Through UPR Activation and Suppression of c‑Myc and BCL2 in Multiple Myeloma.

Oct 15, 2025 |


×

Privacy Policy Updates

Please read carefully the Knoa Pharma LLC Privacy Policy (the "Privacy Policy"), which is part of the Knoa Pharma LLC Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service"). This Privacy Policy describes the information collected through your use of the Service, how we use it, how we share it, how we protect it, and the choices you can make about your information.